InterVenn Investigator Initiated Research Program in Glycoproteomics

Leverage the Power of Glycoproteomics with Speed, Scope, and Scale

InterVenn offers comprehensive glycoproteomic services with a new platform called perspectIV™.

The perspectIV platform offers new insights into cellular and protein function through characterization of glycoproteins. The key advantage of investigating the glycoproteome, as compared to the proteome, is that it provides access to a layer of biology, post-translational glycosylation, which importantly affects protein function in health and disease, adding orders of magnitude richer information about biology.

perspectIV is the first commercially available platform capable of rapidly and comprehensively interrogating glycosylation across the proteome, hypothesis-free or targeted, from serum, plasma, or tissue.

CONTACT US TO LEARN MORE.

Powered by AI and advanced machine learning techniques, InterVenn’s perspectIV platform, can do in minutes what would take a human operator months to achieve.

Comprehensive Glycoproteomic Services

Glycoproteomics, cutting-edge mass spectrometry, AI machine learning

Biomarker Discovery (Contract Research Services, data analysis, informatics support, multi-omic data integration)

Clinical Laboratory (CLIA laboratory, LDT validation, trials and regulatory support)

Commercialization (support send-out testing, commercial sales, customer-excellence team)

InterVenn's multidisciplinary glycoproteomic expertise seamlessly integrates novel insights into your research.

Accessioning and Extraction

Sample Preparation and Enzymatic Digestion

Separation and Identification by Liquid Chromatography-Mass Spectrometry (LCMS)

Proprietary AI & Machine Learning

Reporting

InterVenn has developed a complete "sample to result" glycoproteomic solution.

Our scientists simplify the process to analyze and work with your team to help interpret the data.

Our perspectIV Platform Paves the Path for Success

Intervenn’s fully integrated services, tailored to your needs, help you achieve your research objectives. Accelerate your research by leveraging our expertise to deliver immediate insights.

CONTACT US TO DISCUSS YOUR PROJECT.

Partner With Us:

Biotechnology and Pharmaceutical Companies
Opportunities
  • Drug Discovery for Novel Targets
  • Biomarker Co-Discovery and Co-Validation
  • Patient Stratification, Monitoring, and Prediction
  • Assay Development and Optimization
  • Novel Insights Into Potential Clinical Endpoints
  • Multi-Omic Complementary Approach
  • Companion Diagnostic Expertise
Benefits
  • CLIA Certified Laboratory
  • No Capital Investment
  • Quick Path from Sample to Results
  • Access to Glycoproteomic Experts and The Latest Technologies
  • Full Service from Discovery to Commercialization
Academic Medical Centers
Opportunities
  • Drug Discovery for Novel Targets
  • Biomarker Discovery and Validation
  • Patient Stratification, Monitoring, and Prediction
  • Novel Insights Into Potential Clinical Endpoints
  • Multi-Omic Complementary Approach
Benefits
  • CLIA Certified Laboratory
  • No Capital Investment
  • Quick Path from Sample to Results
  • Access to Glycoproteomic Experts and The Latest Technologies
  • Full Service from Discovery to Commercialization
In-Vitro Diagnostic Companies
Opportunities
  • Biomarker Discovery and Validation
  • Assay Development and Optimization
  • Novel Insights Into Potential Clinical Endpoints
  • Multi-Omic Complementary Approach
  • Companion Diagnostic Expertise
Benefits
  • CLIA Certified Laboratory
  • No Capital Investment
  • Quick Path from Sample to Results
  • Access to Glycoproteomic Experts and The Latest Technologies
  • Full Service from Discovery to Commercialization
Contract Research Organizations
Opportunities
  • Biomarker Discovery and Validation
  • Assay Development and Optimization
  • Novel Insights Into Potential Clinical Endpoints
  • Multi-Omic Complementary Approach
  • Companion Diagnostic Expertise
Benefits
  • CLIA Certified Laboratory
  • No Capital Investment
  • Quick Path from Sample to Results
  • Access to Glycoproteomic Experts and The Latest Technologies
  • Full Service from Discovery to Commercialization
Imaging Companies
Opportunities
  • Biomarker Discovery and Validation
  • Assay Development and Optimization
  • Novel Insights Into Potential Clinical Endpoints
  • Multi-Omic Complementary Approach
  • Companion Diagnostic Expertise
Benefits
  • CLIA Certified Laboratory
  • No Capital Investment
  • Quick Path from Sample to Results
  • Access to Glycoproteomic Experts and The Latest Technologies
  • Full Service from Discovery to Commercialization

Glycoproteins: Bringing Precision Medicine to a New Level

  • As an independent test
  • In combination with standard-of-care assessments
  • As a complement to current testing modalities

Glycosylation is a post-translational language of biology, and InterVenn’s platform enables interrogation of the glycosylation status of any protein.

Prostate-Specific Antigen PSA;
The Diagnostic Performance of Testing Protein Vs. Glycosylated Protein

PSA is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the level of PSA in male subjects’ blood. The blood level of PSA is often elevated in men with prostate cancer even though other conditions such as prostatitis (inflammation of the prostate) and benign prostatic hyperplasia BPH may cause PSA elevations.

In a study by Hoffman et al., typical PSA tests, which only measure the abundance of the PSA protein, had an area-under-curve ‘AUC’ of 0.60 as depicted in figure on the right. Top figure shows an illustration of the PSA Protein structure.

In another study by Llop et al., glycosylatedPSA were shown to be differentially expressed in prostate cancer cohort when compared to the BPH cohort. Measuring core fucosylation and sialylation reported an AUC of 0.94 as depicted in the figure on the right. Bottom figure shows an illustration of the PSA protein structure with glycans.

Cancer.Gov. Accessed March 21, 2022 https://www.cancer.gov/types/prostate/psa-fact-sheet
Hoffman, R.M. et al. BMC Family Practice 2002, 319. https://bmcprimcare.biomedcentral.com/track/pdf/10.1186/1471-2296-3-19.pdf
Llop E., et al. Theranostics 2016; 68 11901204. doi: 10.7150/thno.15226 https://www.thno.org/v06p1190.pdf
1. Copyright © 2002 Hoffman et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article’s original URL. Full article available at https://bmcprimcare.biomedcentral.com/track/pdf/10.1186/1471-2296-3-19.pdf.
2. Copyright © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution CC BYNC 4.0 License. See http://ivyspring.com/terms for full terms and conditions. Full article available at https://www.thno.org/v06p1190.htm. Figure modified.

Get Started

Get to know more about Intervenn’s comprehensive glycoproteomics services and how they can facilitate your clinical research.

Get information about Intervenn’s Glycoproteomics services